1. Daily multidisciplinary COVID-19 meeting: experiences from a French university hospital
- Author
-
Audrey Milon, Floriane Millet, Michel Denis, Pascaline Choinier, Jean Simon Rech, Nicolas Belaube, Corinne Amiel, Deborah Sroussi, Jacques Cadranel, Martine Nadal, Muriel Fartoukh, Camille Rolland-Debord, Isabelle Debrix, Camille Petit-Hoang, Sophie Georgin-Lavialle, Antoine Parrot, S. Mattioni, Pierre Rigaud, A. Canellas, Ludovic Lassel, Emmanuelle Blin, Martin Siguier, Service de Pneumologie et Réanimation Médicale [CHU Pitié-Salpêtrière] (Département ' R3S '), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Médecine Interne [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon]
- Subjects
Pulmonary and Respiratory Medicine ,Male ,medicine.medical_specialty ,Standard of care ,Coronavirus disease 2019 (COVID-19) ,Clinical Decision-Making ,prospective cohorts ,030204 cardiovascular system & hematology ,World health ,Article ,Hospitals, University ,Multidisciplinary meetings ,03 medical and health sciences ,0302 clinical medicine ,Multidisciplinary approach ,medicine ,Medical Staff, Hospital ,therapeutic trials ,Humans ,030212 general & internal medicine ,Medical prescription ,Aged ,Aged, 80 and over ,business.industry ,COVID-19 ,Middle Aged ,University hospital ,Therapeutic trial ,3. Good health ,Group Processes ,standard of care ,Family medicine ,Cohort ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Female ,France ,business - Abstract
International audience; ObjectivesIn March 2020, the World Health Organization declared the coronavirus disease 2019 (COVID-19) a pandemic. In absence of official recommendations, implementing daily multidisciplinary team (MDT) COVID-19 meetings was urgently needed. Our aim was to describe our initial institutional standard operating procedures for implementing these meetings, and their impact on daily practice.MethodsAll consecutive patients who were hospitalized in our institution due to COVID 19, from March 31 to April 15, 2020, were included. Criteria to be presented at MDT meetings were defined as a proven COVID-19 by PCR or strongly suspected on CT scan, requiring hospitalization and treatment not included in the standard of care. Three investigators identified the patients who met the predefined criteria and compared the treatment and outcomes of patients with predefined criteria that were presented during MDT meeting with those not presented during MDT meeting. COVID-19 MDT meeting implementation and adhesion were also assessed by a hospital medical staff survey.ResultsIn all, 318 patients with confirmed or suspected COVID-19 were examined in our hospital. Of these, 230 (87%) were hospitalized in a COVID-19 unit, 91 (40%) of whom met predefined MDT meeting criteria. Fifty (55%) patients were presented at a MDT meeting versus 41 (45%) were not. Complementary exploration and inclusion in the CorImmuno cohort were higher in MDT meeting group (respectively 35 vs. 15%, P = 0.03 and 80 versus 49%, P = 0.0007). Prescription of hydrocortisone hemisuccinate was higher in group of patients not presented during MDT meeting (24 vs. 51%, P = 0.007). Almost half of the patients fulfilling the inclusion criteria were not presented at MDT meeting, which can be partly explained by technical software issues.ConclusionsMultidisciplinary COVID-19 meetings helped implementing a single standard of care, avoided using treatments that were untested or currently being tested, and facilitated the inclusion of patients in prospective cohorts and therapeutic trials.
- Published
- 2021
- Full Text
- View/download PDF